Direct and Complement Dependent Cytotoxicity in CLL Cells from Patients with High Risk Early Stage Chronic Lymphocytic Leukemia (CLL) Treated with Alemtuzumab and Rituximab

The mechanism of cytotoxicity of alemtuzumab and rituximab in CLL is not well understood. We obtained fresh CLL cells from early stage high risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. Alemtuzumab had minimal direct cytotoxicity b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zent, Clive S., Secreto, Charla R., LaPlant, Betsy R., Bone, Nancy D., Call, Timothy G., Shanafelt, Tait D., Jelinek, Diane F., Tschumper, Renee C., Kay, Neil E.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2588544/
https://ncbi.nlm.nih.gov/pubmed/18584865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.05.014
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars